In this study, the mutant KRAS detection rate in patients with localizedPDAC after surgical resection dropped from 66.7% before surgery to 5% after surgery,indicating that EV-associated KRAS mutations could serve as biomarkers for real-timemonitoring of therapy response and tumor burden[143]. This evidence concerns the gene KRAS and neoplasm.